Sector Expert: Ching-Yi Lin

H.C. Wainwright & Co.



Recent Quotes

"STEM has included stricter patient criteria in its Phase 2 dry AMD trial."

— Ching-Yi Lin, H.C. Wainwright & Co. (8/7/15)
more >

"In STEM's dry AMD study, both cohorts showed safety and tolerability."

— Ching-Yi Lin, H.C. Wainwright & Co. (6/30/15)
more >

"We are initiating STEM with a Buy rating."

— Ching-Yi Lin, H.C. Wainwright & Co. (5/18/15)
more >



Due to permission requirements, not all quotes are shown.